0000950170-24-009505.txt : 20240131 0000950170-24-009505.hdr.sgml : 20240131 20240131174505 ACCESSION NUMBER: 0000950170-24-009505 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240129 FILED AS OF DATE: 20240131 DATE AS OF CHANGE: 20240131 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kulkarni Samarth CENTRAL INDEX KEY: 0001682019 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37923 FILM NUMBER: 24584163 MAIL ADDRESS: STREET 1: C/O CRISPR THERAPEUTICS AG STREET 2: 200 SIDNEY STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CRISPR Therapeutics AG CENTRAL INDEX KEY: 0001674416 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 473173478 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 BUSINESS PHONE: 6173154600 MAIL ADDRESS: STREET 1: BAARERSTRASSE 14 CITY: ZUG STATE: V8 ZIP: CH-6300 4 1 ownership.xml 4 X0508 4 2024-01-29 0001674416 CRISPR Therapeutics AG CRSP 0001682019 Kulkarni Samarth C/O CRISPR THERAPEUTICS 105 WEST FIRST STREET BOSTON MA 02127 true true false false Chief Executive Officer true Common Shares 2024-01-29 4 M false 50000 19.12 A 237377 D Common Shares 2024-01-29 4 S false 49300.00 60.5031 D 188077 D Common Shares 2024-01-29 4 S false 700.00 61.0998 D 187377 D Common Shares 200000 I The Kulkarni 2023 GRAT Stock Option (Right to Buy) 19.12 2024-01-29 4 M false 50000 D 2027-12-01 Common Shares 50000 100000 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 15, 2023 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.04 to $61.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.04 to $61.155, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. This performance-based stock option was granted on December 1, 2017 with respect to 150,000 Common Shares and was subject to both time- and performance-based vesting. Performance-based stock options vested as to 112,500 options on December 1, 2020 and 37,500 options on December 1, 2021, based on the Company's performance over the applicable performance period, and subject to the terms and conditions of the agreement evidencing the award and the Company's 2016 Stock Option and Incentive Plan. Not applicable. /s/ Elizabeth Ryland Waldinger, attorney-in-fact 2024-01-31